CR vs NPO: Which Is the Better Buy in 2026?
Last updated August 2026
Short answer
CR and NPO are similarly sized, but CR trades noticeably cheaper on forward earnings (27.29x vs 31.81x): the market is paying up for NPO's profile and pricing CR more conservatively, or for faster growth. Which you prefer comes down to the drivers you believe, and whether adding either over-concentrates what you already own.
CR vs NPO: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | CR | NPO | What it tells you |
|---|---|---|---|
| Forward P/E | 27.29 | 31.81 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 37.32 | 168.12 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 1.09 | 1.56 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 76% of range | 77% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 5.65 | 4.62 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: CR is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how CR and NPO affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CR and NPO share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CR and NPO exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Crane Company (CR) do?
Crane Company became a standalone public company in April 2023 when Crane Holdings separated into two businesses, with the industrial operations listing as CR (the payments-and-authentication side became Crane NXT). The company runs two segments: Aerospace & Advanced Technologies, which supplies power conversion, actuation, sensing and thermal-management systems for commercial aircraft, military platforms and space, and Process Flow Technologies, which makes valves, pumps, instrumentation and cryogenic systems for chemical, pharmaceutical, water and energy customers.
What does Enpro (NPO) do?
Enpro Inc. designs and manufactures engineered industrial products across two reporting segments. Sealing Technologies, roughly two-thirds of revenue, sells gaskets, seals, wheel-end components and compositional analysis equipment under the Garlock, STEMCO and Technetics Group brands into general industrial, aerospace, commercial vehicle, food and biopharmaceutical end markets. Advanced Surface Technologies (AST) is the semiconductor-facing half of the story: NxEdge, Technetics Semi, LeanTeq and Alluxa supply precision cleaning, coating and refurbishment services for chamber components used in leading-edge chip production, plus optical thin-film coatings. Both segments sell consumable or service-like content rather than capital equipment, which is why the company keeps talking about recurring aftermarket demand rather than one-off machine sales.
CR vs NPO: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- CR drivers: Aerospace and defense demand; Process Flow Technologies and cryogenics.
- NPO drivers: Advanced Surface Technologies and leading-edge chip demand; Sealing Technologies margin durability and bolt-on acquisitions.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Crane trades at a premium valuation (around 30 times earnings), so any slowdown in growth or margin misstep could pressure the stock. For NPO, valuation carries most of the downside here: at roughly 36 times the midpoint of 2026 adjusted EPS guidance and around 23 times guided adjusted EBITDA, the shares assume the semiconductor upcycle persists.
CR or NPO: which should you pick?
CR vs NPO: the full fundamentals
CR. Crane reported roughly 25% net-sales growth in Q1 2026 (about 4% organic plus acquisitions) and raised full-year adjusted EPS guidance. Adjusted operating margin was near 19.8% while GAAP EPS declined on acquisition-related items. The shares carry a premium multiple around 30 times earnings, reflecting expectations for continued growth.
NPO. Against a market capitalization near ~$7.3 billion, Enpro trades at roughly 36 times the midpoint of its 2026 adjusted EPS guidance and about 6 times TTM revenue, multiples that sit well above where diversified sealing manufacturers historically cleared. Trailing GAAP earnings are a poor guide right now because a ~$67.2 million pension settlement charge and higher environmental reserves suppressed reported net income to ~$44 million over the last twelve months. The quarterly dividend of $0.32 per share annualizes to roughly a 0.4% yield, so income is incidental to the case.
Headline figures (approximate, July 2026): CR shows revenue (ttm) ~$2.5B, q1 2026 revenue ~$696M (+25% YoY), adjusted eps (q1 2026) ~$1.65 (+15% YoY), fy2026 adjusted eps guidance ~$6.65 to $6.85; NPO shows revenue (ttm) ~$1.22B, q2 2026 sales ~$338.8M (+17.6% YoY, ~10.9% organic), adjusted ebitda margin (q2 2026) ~25.6%, 2026 adjusted eps guidance ~$9.30 to ~$9.80.
The bottom line: CR vs NPO
CR and NPO are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CR and NPO exposure against your real portfolio. It is not an investment adviser.
Wondering how CR or NPO fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Crane Company with AI
Connect the broker you already use and ask Walnut's AI how CR fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between CR and NPO?
+
Crane Company became a standalone public company in April 2023 when Crane Holdings separated into two businesses, with the industrial operations listing as CR (the payments-and-authentication side became Crane NXT). Enpro Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is CR or NPO the better stock?
+
Neither is universally better; they suit different views and risk levels. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, CR or NPO?
+
On forward P/E (as of August 2026), CR trades at 27.29x and NPO at 31.81x, so CR is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both CR and NPO?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of CR vs NPO?
+
CR: Crane trades at a premium valuation (around 30 times earnings), so any slowdown in growth or margin misstep could pressure the stock. Reported GAAP EPS fell sharply in Q1 2026 on acquisition-related charges, and integrating deals like the Baker Hughes assets carries execution risk. Guidance assumes a possible decline in the high-margin commercial aerospace aftermarket, citing elevated oil prices and Middle East travel disruptions. The Process Flow business is cyclical and exposed to chemical, energy and industrial capital spending. Defense revenue depends on government budgets and program timing. NPO: Valuation carries most of the downside here: at roughly 36 times the midpoint of 2026 adjusted EPS guidance and around 23 times guided adjusted EBITDA, the shares assume the semiconductor upcycle persists. AST demand is tied to a concentrated set of leading-edge chipmakers whose capital spending can pause abruptly, and a digestion phase would hit the highest-growth, highest-expectation part of the portfolio first. Trailing GAAP results look far weaker than adjusted results, with TTM GAAP diluted EPS near ~$2.06 against ~$9.55 of guided adjusted EPS, a gap created largely by a ~$67.2 million non-cash pension settlement charge in the fourth quarter of 2025 and a ~$16.1 million increase in legacy environmental reserves in the second quarter of 2026. Those legacy environmental obligations, inherited from decades of industrial operations including the asbestos history resolved through the Garlock trust settlement, can be re-estimated upward again. Cyclical pressure also persists in North American commercial vehicle markets and European general industrial and food and biopharmaceutical demand, and the recent acquisition cadence adds integration risk on top of it.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell CR or NPO; figures are approximate and dated (as of August 2026). Verify current data before investing.